Poland· PL-100143311
Nevanac
A nepafenac product containing nepafenacum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 14 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Nepafenac is registered in 14 of 19 countries.
Countries holding a registration under ATC S01BC10 (nepafenac), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 8 of them publish a price we can compare per daily dose
Nepafenac · ATC S01BC10
14 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Nepafenacum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- S01BC10
- ATC class
- Nepafenac
- Defined daily dose
- 0.15 mg, AT
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 2
- gtin07613421058890
- gtin05909991063429
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
81 interactions on record for nepafenac.
Graded by severity as the source publishes them — 81 moderate. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Nepafenac · interactions on record
81 records
- 81 moderate
Most severe, free to view
- DicoumarolB01AA01moderate
- WarfarinB01AA03moderate
- HeparinB01AB01moderate
- Antithrombin IIIB01AB02moderate
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Nepafenac in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- NorwayNevanacNovartis Pharma GmbH
- CzechiaNEVANACNovartis Europharm Limited, Dublin
- United StatesILEVROHarrow Eye, LLC
- BelgiumNevanac 3 mg/mlNovartis Europharm
- NetherlandsNevanac 3 mg/ml oogdruppels, suspensieNovartis Europharm Limited
- SwedenNEVANAC 3 mg/ml Ögondroppar, suspensionNovartis Europharm Limited
- IcelandNevanacNovartis Europharm Limited*
- FinlandNevanacNovartis Europharm Limited
Authorised across Europe · EMA
The same active substance is authorised in 4 EEA countries. Names it is sold under:
- Bulgaria · Апфекто
- Iceland · Nevanac
- Liechtenstein · Nevanac
- Norway · Nevanac
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c68a3dc4-c292-4a72-9951-233560c34f6c GET /v1/drugs/c68a3dc4-c292-4a72-9951-233560c34f6c?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Krople do oczu, zawiesina",
"source": "urpl",
"strength": "3 mg/ml",
"packaging": "05909991063429 ¦ Rp ¦ EU/1/07/433/002 ¦ 26432\n1 butelka 3 ml\n07613421058890 ¦ Rp ¦ EU/1/07/433/003 ¦ 105603\n1 butelka 3 ml",
"substance": "Nepafenac 3 mg/ml",
"common_name": "Nepafenacum",
"pl_product_id": "100143311",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about nepafenac.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.